|Nymox Pharmaceutical Corporation|
9900 Cavendish Boulevard
QC H4M 2V2
Canada - Map
Nymox Pharmaceutical Corporation, a biopharmaceutical company, is engaged in the research and development of products for the aging population. It provides NicAlert and TobacAlert products that use urine or saliva to detect use of and exposure to tobacco products, as well as AlzheimAlert, a proprietary urine assay that aid physicians in the diagnosis of Alzheimers disease. The companys products under development include NX-1207, which in Phase III clinical trials for the treatment of benign prostatic hyperplasia and localized prostate cancer, as well as in human clinical trials to treat hepatocellular carcinoma; and NXC-4720, an anti-bacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, and for the treatment of urinary tract and other bacterial infections in humans. Its products under development also comprise NXB-4221 for the treatment of chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. In addition, the company is involved in the research and development of drugs at various treatments for Alzheimer's disease and other indications; drugs for the treatment of Alzheimers disease that targets spherons; and neural thread protein-based drugs. Further, it develops proprietary diagnostic products; has U.S. patents for using saliva to determine cholesterol levels and for a method of testing for osteoporosis; and owns patent rights to several novel biochemical indicators for Alzheimers disease. The company markets its tests through marketing arm and distributors in North America, Europe and Asia, as well as TobacAlert through online at tobacalert.com. Nymox Pharmaceutical Corporation has license and collaboration agreement with Recordati Ireland Ltd. for the development and commercialization of NX-1207. The company was founded in 1989 and is headquartered in Saint-Laurent, Canada.
|Dr. Paul Averback M.D., DABP,
Founder, Chairman, Chief Exec. Officer, Pres and Member of Communications Committee
|Mr. Andre Monette CPA, CA, CFA,
Chief Financial Officer, Treasurer and Sec.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|